• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COPD 恶化率、健康状况和死亡率——潜在干预措施的综述。

Exacerbation rate, health status and mortality in COPD--a review of potential interventions.

机构信息

Department of Clinical Medical Sciences, University of the West Indies, St. Augustine Campus, Trinidad and Tobago.

出版信息

Int J Chron Obstruct Pulmon Dis. 2009;4:203-23. doi: 10.2147/copd.s3385. Epub 2009 Jun 11.

DOI:10.2147/copd.s3385
PMID:19554195
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2699821/
Abstract

COPD is prevalent in Western society and its incidence is rising in the developing world. Acute exacerbations of COPD, about 50% of which are unreported, lead to deterioration in quality of life and contribute significantly to disease burden. Quality of life deteriorates with time; thus, most of the health burden occurs in more severe disease. COPD severity and frequent and more severe exacerbations are all related to an increased risk of mortality. Inhaled corticosteroids (ICS) have similar effects on quality of life but ICS/long-acting bronchodilator combinations and the long-acting antimuscarinic tiotropium all improve health status and exacerbation rates and are likely to have an effect on mortality but perhaps only with prolonged use. Erythromycin has been shown to decrease the rate of COPD exacerbations. Pulmonary rehabilitation and regular physical activity are indicated in all severities of COPD and improve quality of life. Noninvasive ventilation is associated with improved quality of life. Long-term oxygen therapy improves mortality but only in hypoxic COPD patients. The choice of an inhaler device is a key component of COPD therapy and this requires more attention from physicians than perhaps we are aware of. Disease management programs, characterized as they are by patient centeredness, improve quality of life and decrease hospitalization rates. Most outcomes in COPD can be modified by interventions and these are well tolerated and have acceptable safety profiles.

摘要

COPD 在西方社会中普遍存在,其发病率在发展中国家正在上升。COPD 的急性加重,其中约 50%未报告,导致生活质量恶化,并对疾病负担有重大贡献。生活质量随时间恶化;因此,大部分健康负担发生在更严重的疾病中。COPD 的严重程度、频繁和更严重的恶化都与死亡率的增加有关。吸入性皮质类固醇(ICS)对生活质量有相似的影响,但 ICS/长效支气管扩张剂联合制剂和长效抗毒蕈碱替托品都能改善健康状况和恶化率,并可能对死亡率产生影响,但可能仅在长期使用时。红霉素已被证明可降低 COPD 恶化的发生率。肺康复和定期体育锻炼适用于 COPD 的所有严重程度,并改善生活质量。无创通气与生活质量的改善有关。长期氧疗可改善死亡率,但仅在低氧性 COPD 患者中。吸入器装置的选择是 COPD 治疗的关键组成部分,这需要医生比我们意识到的更多关注。以患者为中心的疾病管理计划可改善生活质量并降低住院率。COPD 的大多数结局都可以通过干预来改变,这些干预措施耐受性良好,安全性可接受。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b3b/2699821/fecc9f0e5813/copd-4-203f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b3b/2699821/fecc9f0e5813/copd-4-203f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b3b/2699821/fecc9f0e5813/copd-4-203f1.jpg

相似文献

1
Exacerbation rate, health status and mortality in COPD--a review of potential interventions.COPD 恶化率、健康状况和死亡率——潜在干预措施的综述。
Int J Chron Obstruct Pulmon Dis. 2009;4:203-23. doi: 10.2147/copd.s3385. Epub 2009 Jun 11.
2
Overuse of long-acting β-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns.慢性阻塞性肺疾病患者长效β受体激动剂/吸入性糖皮质激素的过度使用:是时候重新思考处方模式了。
Postgrad Med. 2023 Nov;135(8):784-802. doi: 10.1080/00325481.2023.2284650. Epub 2024 Jan 10.
3
Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β-agonist bronchodilators.目前有证据表明,使用长效抗胆碱能药物/长效β受体激动剂双支气管扩张剂治疗 COPD 有效。
Postgrad Med. 2020 Mar;132(2):198-205. doi: 10.1080/00325481.2019.1702834. Epub 2020 Jan 3.
4
Role of Long-Acting Muscarinic Antagonist/Long-Acting β-Agonist Therapy in Chronic Obstructive Pulmonary Disease.长效毒蕈碱拮抗剂/长效β受体激动剂疗法在慢性阻塞性肺疾病中的作用
Ann Pharmacother. 2017 Aug;51(8):696-705. doi: 10.1177/1060028017705149. Epub 2017 Apr 14.
5
Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.双重联合疗法与长效支气管扩张剂单药治疗慢性阻塞性肺疾病(COPD)的疗效比较:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2018 Dec 3;12(12):CD012620. doi: 10.1002/14651858.CD012620.pub2.
6
Impact and prevention of severe exacerbations of COPD: a review of the evidence.慢性阻塞性肺疾病严重加重的影响与预防:证据综述
Int J Chron Obstruct Pulmon Dis. 2017 Oct 5;12:2891-2908. doi: 10.2147/COPD.S139470. eCollection 2017.
7
Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.吸入性皮质类固醇联合吸入长效β2-激动剂和长效抗胆碱能药物治疗慢性阻塞性肺疾病。
Cochrane Database Syst Rev. 2023 Dec 6;12(12):CD011600. doi: 10.1002/14651858.CD011600.pub3.
8
Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.联合使用皮质类固醇和长效β2受体激动剂的单一吸入器与长效β2受体激动剂治疗慢性阻塞性肺疾病的比较
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD006829. doi: 10.1002/14651858.CD006829.pub2.
9
Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.慢性阻塞性肺疾病:对有反复症状的患者有用的药物。
Prescrire Int. 2016 Nov;25(176):272-277.
10
Management goals and stable phase management of patients with chronic obstructive pulmonary disease in the Japanese respiratory society guideline for the management of chronic obstructive pulmonary disease 2022 (6th edition).日本呼吸学会慢性阻塞性肺疾病管理指南 2022 年(第 6 版):慢性阻塞性肺疾病患者的管理目标和稳定期管理。
Respir Investig. 2023 Nov;61(6):773-780. doi: 10.1016/j.resinv.2023.08.007. Epub 2023 Sep 21.

引用本文的文献

1
Chronic Obstructive Pulmonary Disease and Metabolic Syndrome: A Maltese Study on Biomarkers and Clinical Implications.慢性阻塞性肺疾病与代谢综合征:一项关于生物标志物及临床意义的马耳他研究
Diabetes Metab Syndr Obes. 2025 Jul 21;18:2463-2476. doi: 10.2147/DMSO.S515061. eCollection 2025.
2
CAT score as a prognostic tool in low resource setting: Exploring the correlation between CAT score, exacerbation history with BODE Index in stable COPD.在资源匮乏环境中,CAT评分作为一种预后工具:探究稳定期慢性阻塞性肺疾病患者CAT评分、急性加重病史与BODE指数之间的相关性
Lung India. 2025 Jul 1;42(4):343-346. doi: 10.4103/lungindia.lungindia_633_24. Epub 2025 Jun 27.
3

本文引用的文献

1
Obstructive lung disease in acute medical patients.急性内科患者的阻塞性肺疾病
West Indian Med J. 2008 Jan;57(1):7-13.
2
[Circulating air and captive air in the exploration of the pulmonary ventilator function].[循环空气与滞留空气在肺通气功能探索中的作用]
Paris Med. 1947 Dec 27;37(52):624-8.
3
A 4-year trial of tiotropium in chronic obstructive pulmonary disease.噻托溴铵用于慢性阻塞性肺疾病的4年试验。
Exploring the possibility of a predictable precision therapy of COPD with inclusion of glycopyrronium responsiveness: A real-world experience.
探索将格隆溴铵反应性纳入慢性阻塞性肺疾病(COPD)可预测精准治疗的可能性:一项真实世界经验。
Lung India. 2025 Jul 1;42(4):322-329. doi: 10.4103/lungindia.lungindia_54_25. Epub 2025 Jun 27.
4
Exacerbating the Problem: COPD and Atrial Fibrillation.问题加剧:慢性阻塞性肺疾病与心房颤动
Am J Respir Crit Care Med. 2025 Mar 12;211(5):695-7. doi: 10.1164/rccm.202501-0229ED.
5
Cumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPD.慢性阻塞性肺疾病患者12个月内口服皮质类固醇的累积配药量
Int J Chron Obstruct Pulmon Dis. 2025 Jan 20;20:149-158. doi: 10.2147/COPD.S491654. eCollection 2025.
6
Implementation of an algorithm for predicting exacerbations in telemonitoring: A multimethod study of patients' and clinicians' experiences.远程监测中预测病情加重算法的实施:一项关于患者和临床医生体验的多方法研究
Int J Nurs Stud Adv. 2024 Oct 22;7:100257. doi: 10.1016/j.ijnsa.2024.100257. eCollection 2024 Dec.
7
Prognostic risk prediction model for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD): a systematic review and meta-analysis.慢性阻塞性肺疾病急性加重(AECOPD)患者预后风险预测模型:系统评价和荟萃分析。
Respir Res. 2024 Nov 14;25(1):410. doi: 10.1186/s12931-024-03033-4.
8
Impact of Body Mass Index on Risk of Exacerbation in Patients With COPD: A Systematic Review and Meta-Analysis.体重指数对慢性阻塞性肺疾病患者病情加重风险的影响:一项系统评价与荟萃分析
Chronic Obstr Pulm Dis. 2024 Sep 27;11(5):524-533. doi: 10.15326/jcopdf.2024.0507.
9
Rate of severe exacerbations, healthcare resource utilisation and clinical outcomes in patients with COPD in low-income and middle-income countries: results from the EXACOS International Study.低收入和中等收入国家 COPD 患者严重加重率、医疗资源利用和临床结局:EXACOS 国际研究结果。
BMJ Open Respir Res. 2024 Apr 18;11(1):e002101. doi: 10.1136/bmjresp-2023-002101.
10
Public Health Relevance of US EPA Air Quality Index Activity Recommendations.美国环保署空气质量指数活动建议的公共卫生相关性。
JAMA Netw Open. 2024 Apr 1;7(4):e245292. doi: 10.1001/jamanetworkopen.2024.5292.
N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.
4
Exacerbations and intent-to-treat analyses in randomised trials.随机试验中的病情加重情况及意向性分析。
Eur Respir J. 2008 Oct;32(4):1117-8. doi: 10.1183/09031936.00108308.
5
Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.吸入性抗胆碱能药物与慢性阻塞性肺疾病患者主要不良心血管事件风险:一项系统评价和荟萃分析
JAMA. 2008 Sep 24;300(12):1439-50. doi: 10.1001/jama.300.12.1439.
6
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.长期使用红霉素治疗与慢性阻塞性肺疾病急性加重次数减少有关。
Am J Respir Crit Care Med. 2008 Dec 1;178(11):1139-47. doi: 10.1164/rccm.200801-145OC. Epub 2008 Aug 21.
7
Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.长效支气管扩张剂与吸入性类固醇联合治疗慢性阻塞性肺疾病的成本效益
Thorax. 2008 Nov;63(11):962-7. doi: 10.1136/thx.2007.089557. Epub 2008 Jul 11.
8
Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited.慢性阻塞性肺疾病急性加重率的统计分析:重新审视TRISTAN和ISOLDE研究
Eur Respir J. 2008 Jul;32(1):17-24. doi: 10.1183/09031936.00161507.
9
Age does not hamper the response to pulmonary rehabilitation of COPD patients.年龄不会妨碍慢性阻塞性肺疾病(COPD)患者对肺康复治疗的反应。
Age Ageing. 2008 Sep;37(5):530-5. doi: 10.1093/ageing/afn126. Epub 2008 Jun 19.
10
Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.羧甲司坦对慢性阻塞性肺疾病急性加重的影响(PEACE研究):一项随机安慰剂对照研究
Lancet. 2008 Jun 14;371(9629):2013-8. doi: 10.1016/S0140-6736(08)60869-7.